Table 1.
Patient characteristics
| N,% |
2015 N = 22 |
2016 N = 67 |
2017 N = 81 |
2018 N = 116 |
2019 N = 181 |
2020 N = 100 |
|---|---|---|---|---|---|---|
| HCV genotype | ||||||
| Genotype 1a/b/other | 2/11/0 (9.1/50.0/0) | 24/18/1 (35.8/26.9/1.5) | 23/16/3 (28.4/19.8/3.7) | 28/29/3 (24.1/25.0/2.6) | 36/52/4 (19.9/28.7/2.2) | 31/19/0 (31.0/19.0/0.0) |
| Genotype 2 | 2 (9.1) | 9 (13.4) | 6 (7.4) | 5 (4.3) | 10 (5.5) | 2 (2.0) |
| Genotype 3 | 3 (13.6) | 11 (16.4) | 20 (24.7) | 31 (26.7) | 56 (28.7) | 25 (25.0) |
| Genotype 4 | 4 (18.2) | 3 (4.5) | 7 (8.6) | 14 (12.1) | 10 (5.5) | 7 (7.0) |
| Genotype 5/6 | 0 (0) | 0 (0) | 1 (1.2) | 0 (0) | 1 (0.6) | 0 (0) |
| Unkown | 0 (0) | 1 (1.5) | 5 (6.2) | 6 (5.2) | 12 (6.6) | 16 (7.0) |
| Liver cirrhosis | 11 (50.0) | 12 (17.9) | 11 (13.6) | 23 (19.8) | 37 (20.4) | 24 (24.0) |
| Child Pugh A | 9 (81.8) | 10 (83.3) | 8 (72.7) | 19 (82.6) | 29 (78.4) | 19 (79.2) |
| Child Pugh B/C | 0 (0) | 1 (8.3) | 2 (18.2) | 3 (13.0) | 5 (13.5) | 4 (16.7) |
| Unknown | 2 (18.2) | 1 (8.3) | 1 (9.1) | 1 (4.3) | 3 (8.1) | 1 (4.2) |
| Comorbidities | ||||||
| Chronic kidney disease | 1 (4.5) | 2 (1.5) | 0 (0) | 3 (2.6) | 1 (0.6) | 0 (0) |
| Treatment status | ||||||
| Treatment naïve | 8 (36.4) | 45 (67.2) | 46 (63.0) | 92 (79.3) | 150 (82.9) | 83 (83.0) |
| PEG-IFN-experienced | 13 (59.1) | 18 (26.9) | 23 (31.5) | 15 (12.9) | 20 (11.0) | 12 (12.0) |
| DAA-experienced | 1 (4.5) | 4 (6.0) | 4 (5.5) | 9 (7.8) | 11 (6.1) | 5 (5.0) |
| DAA regimen | ||||||
| ELB/GRZ | - | - | 5 (6.2) | 11 (9.5) | 29 (16.0) | 8 (8.0) |
| GLE/PIB | - | - | - | 46 (39.7) | 76 (42.0) | 69 (69.0) |
| OMV/PTV/RTV + DSV | 5 (22.7) | 7 (10.4) | 3 (3.7) | - | - | - |
| SOF | 4 (18.2) | 2 (3.0) | - | 1 (0.9) | - | - |
| SOF/DCV | 7 (31.8) | 27 (40.3) | 25 (30.9) | 6 (5.2) | - | - |
| SOF/LDV | 4 (18.2) | 30 (44.8) | 32 (39.5) | 15 (12.9) | 2 (1.1) | - |
| SOF/SIM | 2 (9.1) | - | 1 (1.2) | - | - | - |
| SOF/VEL | - | - | 14 (17.3) | 39 (29.3) | 61 (33.7) | 19 (19.0) |
| SOF/VEL/VOX | - | - | 1 (1.2) | 1 (0.9) | 12 (6.6) | 3 (3.0) |
| SOF + GLE/PIB | - | - | - | 2 (1.7) | - | 1 (1.0) |
| Other | - | 1 (1.5) | - | - | 1 (0.6) | - |
| Addition ribavirin | 14 (63.6) | 10 (14.9) | 8 (9.9) | 2 (1.7) | 4 (2.2) | 3 (3.0) |
| SVR | 21 (95.5) | 64 (95.5) | 78 (96.3) | 113 (97.4) | 173 (96.6) | 93 (93.0) |
HCV Hepatitis C virus, PEG-IFN Pegylated interferon, DAA Direct-acting antivirals, ELB Elbasvir, GRZ Grazoprevir, GLE Glecaprevir, PIB Pibrentasvir, OMV Ombitasvir, PTV Paritaprevir, RTV Ritonavir, DSV Dasabuvir, SOF Sofosbuvir, DCV Daclatasvir, LDV Ledipasvir, SIM Simeprevir, VEL Velpatasvir, VOX Voxilaprevir, SVR Sustained virological response